
Category: FFPE
April 3, 2023 / Nat Med
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early recurrence and metastasis. Enoblituzumab is a…
March 15, 2023 / Sci Adv
Digital spatial profiling of intraductal papillary mucinous neoplasms: Toward a molecular framework for risk stratification
The histopathologic heterogeneity of intraductal papillary mucinous neoplasms (IPMN) complicates the prediction of pancreatic ductal adenocarcinoma (PDAC) risk. Intratumoral regions of pancreaticobiliary (PB), intestinal (INT), and gastric foveolar (GF) epithelium…
March 14, 2023 / Cell Rep
Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma
Glioblastoma (GBM) is the most aggressive brain tumor, with a median survival of ∼15 months. Targeted approaches have not been successful in this tumor type due to the large extent of…
March 10, 2023 / Toxins
Mapping the Immune Cell Microenvironment with Spatial Profiling in Muscle Tissue Injected with the Venom of Daboia russelii
Pathological and inflammatory events in muscle after the injection of snake venoms vary in different regions of the affected tissue and at different time intervals. In order to study such…
March 10, 2023 / Cancers
Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer
The identification of transcriptomic and protein biomarkers prognosticating recurrence risk after chemoradiation of localized squamous cell carcinoma of the anus (SCCA) has been limited by a lack of available fresh…
March 9, 2023 / PNAS Nexus
Digital spatial profiling of human parathyroid tumors reveals cellular and molecular alterations linked to vitamin D deficiency
Primary hyperparathyroidism (PHPT) is a common endocrine neoplastic disorder characterized by disrupted calcium homeostasis secondary to inappropriately elevated parathyroid hormone (PTH) secretion. Low levels of serum 25-hydroxyvitamin D (25OHD) are…
March 8, 2023 / Eur Urol
Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer
Background: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective…
March 7, 2023 / J Alzheimers Dis
Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer’s Disease
Background:: Phosphorylated cytoplasmic tau inclusions correlate with and precede cognitive deficits in Alzheimer’s disease (AD). However, pathological tau accumulation and relationships to synaptic changes remain unclear. Objective:: To address this,…
March 3, 2023 / J Invest Dermatol
MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed…
March 1, 2023 / Oncoimmunology
Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
Despite aggressive treatment, the 5-year event-free survival rate for children with high-risk neuroblastoma is
February 28, 2023 / J Immunother Cancer
Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
Background: Immunotherapy for malignant tumors has made great progress, but many patients do not benefit from it. The complex intratumoral heterogeneity (ITH) hindered the in-depth exploration of immunotherapy. Conventional bulk…
February 27, 2023 / Transl Med Commun
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors
Background: This window of opportunity trial evaluated the safety of intratumoral Copaxone® and profiled immune markers in biopsies before and after treatment. Methods: Patients with percutaneously accessible malignancies scheduled for…